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Predicting the incidence and timing of central nervous system 
disease in metastatic melanoma: Implications for surveillance 
and preventative therapy
Gary B. Deutsch, MD, Richard Tyrell, MD, Samuel Yost, BA, Mariel B. Deutsch, MD, Garni 
Barkhoudarian, MD, Daniel F. Kelly, MD, and Mark B. Faries, MD
Hofstra - Northwell School of Medicine (Drs. GB Deutsch and Tyrell), Uniondale, NY; Donald L. 
Morton, MD, Melanoma Research Program (Dr. Faries), Brain Tumor Center (Mr. Yost and Drs. 
Barkhoudarian and Kelly); and the Department of Neurology (Dr. MB Deutsch), Icahn School of 
Medicine at Mount Sinai, New York, NY
Effective systemic therapies have improved survival in advanced melanoma, resulting in a 
higher lifetime risk of brain metastases.1 Male sex, truncal or head / neck location, and thick 
or ulcerated primary lesions are well-accepted risk factors.2 Histologic subtype, however, 
has not been extensively studied. We report one of the largest series of MBM to better define 
clinicopathologic risk factors, guide management and surveillance decisions.
An institutional melanoma database review identified 3,756 patients diagnosed with 
metastatic melanoma between 1971 and 2013. Patients were divided into two groups based 
on whether or not they developed MBM. Primary endpoints were development of MBM and 
two-year melanoma brain metastases-free survival (MBMFS). The secondary endpoint was 
overall survival (OS).
Of 2,132 patients included in the final analysis, 397 (18.6%) of these patients developed 
brain metastases. Univariable analysis identified sex, primary location, ulceration, and 
histologic subtype as predictors of 2-year MBMFS in patients who developed stage IV 
disease (Figure 1). Multivariable analyses demonstrated that axial location (p<0.01), 
presence of ulceration (p=0.04), and desmoplastic (p=0.02) and nodular (p=0.03) 
histological variants were associated with a higher risk of developing MBM. The presence 
of ulceration (p<0.01), axial primary location (p<0.01), desmoplastic histologic subtype 
(p=0.03), and era of stage IV diagnosis (1990–1999 vs. 1970–1979 [p<0.01] and 2000–2009 
vs. 1970–1979 [p=0.01]) were independent predictors of 2-year MBMFS (Table 1). 
Ipilimumab had no significant effect on the incidence or timing of MBM. An inferior 2-year 
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OS was seen with male sex (HR=1.15, p=0.02), older age (HR=1.01, p=0.01), axial location 
(HR=1.14, p=0.03), and ulceration (HR=1.19, p<0.01). Patients treated with ipilimumab 
(HR=0.16, p<0.01) demonstrated improved 2-year OS. Of the patients diagnosed with 
desmoplastic melanoma (n=25), 9 (36%) were found to have MBM, all within the first year 
after the diagnosis of other systemic disease. The primary lesion was greater than 4.0 mm 
deep in 7/9 (78%) and located in the head and neck region in 6/9 (67%).
Proposed mechanisms include travel along the external surface of vessels (angiotropism) and 
nerves (neurotropism). In a case series of 20 patients with MBM, 14 showed angiotropism in 
the primary lesion. The tumors with angiotropism had an average time to MBM of 33 
months, compared to 57 months in the melanomas without angiotropism, although not 
statistically significant.3 The largest series of desmoplastic melanoma described four 
patients with neurotropism involving named nerves of the head and neck.4 Survival after 
diagnosis of stage IV disease has been shown to be significantly lower in patients with 
isolated MBM when compared to multiple metastatic sites.5 Our results differed, perhaps as 
a result of newer treatment options (i.e. stereotactic radiosurgery). Although many of these 
patients are traditionally excluded from clinical trials, our findings suggest they should be 
given equal consideration.
This study identifies desmoplastic subtype as a strong predictor of MBM development and 
decreased 2-year MBMFS. In patients with desmoplastic subtype, particularly thick lesions 
involving the head and neck, serial screening for CNS metastases with brain magnetic-
resonance imaging should be considered during the first year after Stage IV diagnosis.
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Figure 1. 
Univariate predictors of 2-year melanoma brain metastases-free survival of patients with 
eventual stage IV disease. A: patient sex – female 81.7%, male 73.5% (p<0.01); B: primary 
location – ocular 91.5%, mucosal 87.2%, extremity 82.8%, and axial 72.3% (p<0.01); C: 
ulceration – yes 69.0%, no 79.8% (p<0.01); D: histologic subtype – lentigo maligna 89.9%, 
other 83.7%, superficial spreading 76.9%, nodular 72.1%, and desmoplastic 57.8% (p<0.01)
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Table 1
Multivariable predictors of developing MBM among patients that develop stage IV disease
Variables HR P value
Male sex 1.30 0.04
Histology (ref ➔ superficial spreading)
 Nodular 1.14 NS
 Lentigo maligna 0.42 NS
 Desmoplastic 2.27 0.02
 Other 0.84 NS
Primary site (ref ➔ head and neck)
 Lower extremity 0.68 0.04
 Upper extremity 0.59 0.02
 Trunk 0.95 NS
 Mucosal 0.46 NS
 Other/Unknown primary 0.97 <0.01
Ulceration (ref ➔ No)
 Yes 1.49 <0.01
 Unknown 1.14 0.33
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